AKT1 and fatty liver disease: GLP-1 ligands are able to promote the phosphorylation of AKT, an effect that subsequently triggers the postreceptor signaling cascade downstream of insulin receptor substrate-2 (IRS-2), leading to reduced storage of hepatocyte triglycerides and, therefore, reduced hepatic steatosis [39].